FIELD: biotechnology.
SUBSTANCE: disclosed is a conjugate and use thereof for targeted delivery of a haptenilised pharmaceutically active load through a blood-brain barrier. Also disclosed is a pharmaceutical composition containing said conjugate for treating a brain disease. Conjugate of the present invention comprises a haptenylated load and a bispecific antibody which has a first antigen-binding fragment, specifically bound to a haptenilated load, and a second antigen-binding fragment specifically binding to blood-brain barrier receptor, where the first antigen-binding fragment is covalently bonded to the haptenylated load using a cysteine residue at position 52b or 53 of the heavy chain according to Kabat numbering. Covalent bond with hapten provides stabilization of pharmaceutically active load, and presence of second antigen-binding fragment - its transportation through blood-brain barrier.
EFFECT: present invention can find further application in therapy.
14 cl, 63 dwg, 8 tbl, 38 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COVALENTLY LINKED CONJUGATES CHELICAR-ANTIBODY AGAINST CHELICAR AND USE THEREOF | 2014 |
|
RU2694981C2 |
| COVALENT BONDED POLYPEPTIDE TOXIN AND ANTIBODY CONJUGATES | 2014 |
|
RU2682754C2 |
| KOVALENT-RELATED CONJUATES OF ANTIGEN-ANTIBODY | 2013 |
|
RU2684595C2 |
| ANTIBODIES TO BIOTIN AND APPLICATION METHODS | 2013 |
|
RU2630296C2 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
| ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODY IN HETERODIMERIC FORM, SIMILAR IN STRUCTURE TO NATURAL ANTIBODY, AND PRODUCTION THEREOF | 2022 |
|
RU2825838C1 |
| SHUTTLE FOR BLOOD-BRAIN BARRIER | 2019 |
|
RU2754794C2 |
| SHUTTLE FOR BLOOD-BRAIN BARRIER | 2013 |
|
RU2711552C2 |
| ANTIBODIES AGAINST 5-BROMO-2'-DEOXYURIDINE AND METHODS OF USE | 2015 |
|
RU2705299C2 |
